Skip to content

Orsiro 3.5/22/140Recalls & reported problems

Biotronik AG · Class 3 · Implant

All models of Orsiro (49)

Data updated Oct 16, 2026 from official FDA records · Editorial policy

Adverse event reports
2
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 07640130439122), received between Apr 22, 2019 and May 6, 2022 — classified as 2 malfunctions.

The most frequently reported specific device problem is “Failure to Advance” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Most reported problems

Device problems

  • Failure to Advance1
  • Material Deformation1

Patient problems

  • No Clinical Signs, Symptoms or Conditions1
  • No Consequences Or Impact To Patient1

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • MalfunctionMay 6, 2022Material Deformation; Material Deformation

    AN ORSIRO DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT. THE DEVICE WOULD NOT ADVANCE INITIALLY AND WHEN PULLED OUT, THE LEADING EDGE OF THE STENT WAS DAMAGED.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 14310619 ↗
  • MalfunctionApr 22, 2019Failure to Advance; Failure to Advance

    DURING LESION CROSSING THE ORSIRO DRUG-ELUTING STENT SYSTEM COULD NOT PASS THE TORTUOUS AND CALCIFIED LESION.

    Patient problems: No Consequences Or Impact To Patient

    MAUDE report 8537288 ↗

Other Coronary drug-eluting stent devices

All Coronary drug-eluting stent devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page